{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:28:12Z","timestamp":1787318892309,"version":"build-2736575974"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00109-021-02170-3","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T19:03:47Z","timestamp":1641495827000},"page":"411-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A comprehensive review on phytochemicals for fatty liver: are they potential adjuvants?"],"prefix":"10.1007","volume":"100","author":[{"given":"Ta\u00eds Menezes","family":"do Moinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro Le\u00e3o","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5824-8656","authenticated-orcid":false,"given":"Carla R. O.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"issue":"6","key":"2170_CR1","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/hep.25762","volume":"55","author":"N Chalasani","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6):2005\u20132023. https:\/\/doi.org\/10.1002\/hep.25762","journal-title":"Hepatology"},{"issue":"1","key":"2170_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cld.2017.08.007","volume":"22","author":"V Manne","year":"2018","unstructured":"Manne V, Handa P, Kowdley KV (2018) Pathophysiology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Clin Liver Dis 22(1):23\u201337. https:\/\/doi.org\/10.1016\/j.cld.2017.08.007","journal-title":"Clin Liver Dis"},{"issue":"11","key":"2170_CR3","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","volume":"10","author":"R Loomba","year":"2013","unstructured":"Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10(11):686\u2013690. https:\/\/doi.org\/10.1038\/nrgastro.2013.171","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"2170_CR4","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Investig 115(5):1343\u20131351. https:\/\/doi.org\/10.1172\/JCI23621","journal-title":"J Clin Investig"},{"issue":"10","key":"2170_CR5","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s00018-016-2161-x","volume":"73","author":"W Liu","year":"2016","unstructured":"Liu W, Baker RD, Bhatia T, Zhu L, Baker SS (2016) Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci 73(10):1969\u20131987. https:\/\/doi.org\/10.1007\/s00018-016-2161-x","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"2170_CR6","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/hep.20466","volume":"40","author":"JD Browning","year":"2004","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH (2004) Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40(6):1387\u20131395. https:\/\/doi.org\/10.1002\/hep.20466","journal-title":"Hepatology"},{"issue":"2","key":"2170_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.hipert.2017.12.004","volume":"35","author":"LM Ruilope","year":"2018","unstructured":"Ruilope LM, Nunes Filho ACB, Nadruz W, Rodr\u00edguez Rosales FF, Verdejo-Paris J (2018) Obesity and hypertension in Latin America: current perspectives. Hipertension y Riesgo Vascular 35(2):70\u201376. https:\/\/doi.org\/10.1016\/j.hipert.2017.12.004","journal-title":"Hipertension y Riesgo Vascular"},{"issue":"9","key":"2170_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.5830\/CVJA-2012-040","volume":"23","author":"B Adeboye","year":"2012","unstructured":"Adeboye B, Bermano G, Rolland C (2012) Obesity and its health impact in Africa: a systematic review. Cardiovasc J Afr 23(9):512\u2013521. https:\/\/doi.org\/10.5830\/CVJA-2012-040","journal-title":"Cardiovasc J Afr"},{"key":"2170_CR9","doi-asserted-by":"publisher","unstructured":"Lemamsha H, Randhawa\u00a0G, Papadopoulos C (2019)\u00a0Prevalence of overweight and obesity among Libyan men and women. Biomed Res Int 2019. https:\/\/doi.org\/10.1155\/2019\/8531360","DOI":"10.1155\/2019\/8531360"},{"key":"2170_CR10","doi-asserted-by":"publisher","unstructured":"Toselli S, Gualdi-Russo E, Boulos DNK, Anwar WA, Lakhoua C, Jaouadi I, Khyatti M, Hemminki K (2014) Prevalence of overweight and obesity in adults from North Africa. European J Public Health 24(SUPPL.1), 31\u201339. https:\/\/doi.org\/10.1093\/eurpub\/cku103","DOI":"10.1093\/eurpub\/cku103"},{"issue":"1","key":"2170_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/nyas.12433","volume":"1311","author":"NP Steyn","year":"2014","unstructured":"Steyn NP, Mchiza ZJ (2014) Obesity and the nutrition transition in sub-Saharan Africa. Ann N Y Acad Sci 1311(1):88\u2013101. https:\/\/doi.org\/10.1111\/nyas.12433","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"2170_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1467-789X.2006.00237.x","volume":"7","author":"MT Van Der Merwe","year":"2006","unstructured":"Van Der Merwe MT, Pepper MS (2006) Obesity in South Africa. Obes Rev 7(4):315\u2013322. https:\/\/doi.org\/10.1111\/j.1467-789X.2006.00237.x","journal-title":"Obes Rev"},{"key":"2170_CR13","doi-asserted-by":"crossref","unstructured":"Petersen MC, Shulman GI (2018) Mechanisms of insulin action and insulin resistance. Physiol Rev 98(4):2133-2223 10.1023\/A","DOI":"10.1152\/physrev.00063.2017"},{"issue":"6","key":"2170_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/ng1362","volume":"36","author":"B Ravikumar","year":"2004","unstructured":"Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden R, O\u2019Kane CJ, Rubinsztein DC (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36(6):585\u2013595. https:\/\/doi.org\/10.1038\/ng1362","journal-title":"Nat Genet"},{"issue":"2","key":"2170_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152.AMPK","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan K-L (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13(2):132\u2013141. https:\/\/doi.org\/10.1038\/ncb2152.AMPK","journal-title":"Nat Cell Biol"},{"issue":"March","key":"2170_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nature03314.1","volume":"434","author":"JT Rodgers","year":"2005","unstructured":"Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P (2005) Nutrient control of glucose homeostasis through a complex of PGC-1a and SIRT1. Nature 434(March):1\u20136. https:\/\/doi.org\/10.1038\/nature03314.1","journal-title":"Nature"},{"issue":"4","key":"2170_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cmet.2009.02.006.Hepatocyte-specific","volume":"9","author":"A Purushotham","year":"2009","unstructured":"Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X (2009) Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9(4):327\u2013338. https:\/\/doi.org\/10.1016\/j.cmet.2009.02.006.Hepatocyte-specific","journal-title":"Cell Metab"},{"issue":"7147","key":"2170_CR18","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/nature05861","volume":"447","author":"X Li","year":"2007","unstructured":"Li X, Monks B, Ge Q, Birnbaum MJ (2007) Akt\/PKB regulates hepatic metabolism by directly inhibiting PGC-1\u03b1 transcription coactivator. Nature 447(7147):1012\u20131016. https:\/\/doi.org\/10.1038\/nature05861","journal-title":"Nature"},{"issue":"7327","key":"2170_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/nature09584","volume":"468","author":"S Sengupta","year":"2010","unstructured":"Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM (2010) MTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 468(7327):1100\u20131106. https:\/\/doi.org\/10.1038\/nature09584","journal-title":"Nature"},{"issue":"May","key":"2170_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107765","volume":"96","author":"M Ghanbari","year":"2021","unstructured":"Ghanbari M, Momen S, Aghazadeh A, Reza S, Mahmud B, Abdoli M, Dastmalchi N, Safaralizadeh R (2021) Interleukin-1 in obesity-related low-grade inflammation\u202f: From molecular mechanisms to therapeutic strategies. Int Immunopharmacol 96(May):107765. https:\/\/doi.org\/10.1016\/j.intimp.2021.107765","journal-title":"Int Immunopharmacol"},{"key":"2170_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00017.2012","volume":"93","author":"P Trayhurn","year":"2013","unstructured":"Trayhurn P (2013) Hypoxia and adipose tissue function and overview of adipose tissue. Physiol Rev 93:1\u201321. https:\/\/doi.org\/10.1152\/physrev.00017.2012","journal-title":"Physiol Rev"},{"issue":"1","key":"2170_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nm0102-75","volume":"8","author":"V Wallenius","year":"2002","unstructured":"Wallenius V, Wallenius K, Ahr\u00e9n B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8(1):75\u201379. https:\/\/doi.org\/10.1038\/nm0102-75","journal-title":"Nat Med"},{"issue":"5","key":"2170_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ni.2865","volume":"15","author":"J Mauer","year":"2014","unstructured":"Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S, Hausen AC, Schmitz J, Br\u00f6nneke HS, Estevez E, Allen TL, Mesaros A, Partridge L, Febbraio MA, Chawla A, Wunderlich FT, Br\u00fcning JC (2014) Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 15(5):423\u2013430. https:\/\/doi.org\/10.1038\/ni.2865","journal-title":"Nat Immunol"},{"key":"2170_CR24","doi-asserted-by":"publisher","unstructured":"Guilherme A, Virbasius JV, Puri V, Czech MP (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. In Nature Reviews Molecular Cell Biology (Vol. 9, Issue 5, pp. 367\u2013377). Nature Publishing Group. https:\/\/doi.org\/10.1038\/nrm2391","DOI":"10.1038\/nrm2391"},{"key":"2170_CR25","doi-asserted-by":"publisher","unstructured":"Fr\u00fchbeck G, M\u00e9ndez-Gim\u00e9nez L, Fern\u00e1ndez-Formoso JA, Fern\u00e1ndez S, Rodr\u00edguez A (2014) Regulation of adipocyte lipolysis. In Nutrition Res Rev 27(1). https:\/\/doi.org\/10.1017\/S095442241400002X","DOI":"10.1017\/S095442241400002X"},{"key":"2170_CR26","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/ajpendo.00419.2004","volume":"288","author":"T You","year":"2004","unstructured":"You T, Yang R, Lyles MF, Gong D, Nicklas BJ, Yang R, Lyles MF, Gong D, Nicklas BJ (2004) Abdominal adipose tissue cytokine gene expression\u202f: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 288:741\u2013747. https:\/\/doi.org\/10.1152\/ajpendo.00419.2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2170_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cca.2012.12.007","volume":"417","author":"A Yadav","year":"2013","unstructured":"Yadav A, Kataria MA, Saini V, Yadav A (2013) Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 417:80\u201384. https:\/\/doi.org\/10.1016\/j.cca.2012.12.007","journal-title":"Clin Chim Acta"},{"key":"2170_CR28","doi-asserted-by":"publisher","unstructured":"Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423(June). https:\/\/doi.org\/10.1038\/nature01683.1","DOI":"10.1038\/nature01683.1"},{"issue":"16","key":"2170_CR29","doi-asserted-by":"publisher","first-page":"10585","DOI":"10.1074\/jbc.272.16.10585","volume":"272","author":"J Ertl","year":"1997","unstructured":"Ertl J, Gerl M, Preibisch G (1997) Leptin impairs metabolic actions of insulin in isolated rat adipocytes *. J Biol Chem 272(16):10585\u201310593. https:\/\/doi.org\/10.1074\/jbc.272.16.10585","journal-title":"J Biol Chem"},{"issue":"2","key":"2170_CR30","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1074\/jbc.272.2.971","volume":"272","author":"JM Stephens","year":"1997","unstructured":"Stephens JM, Lee J, Pilch PF (1997) Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction *. J Biol Chem 272(2):971\u2013976. https:\/\/doi.org\/10.1074\/jbc.272.2.971","journal-title":"J Biol Chem"},{"issue":"1","key":"2170_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.cmet.2015.09.024","volume":"23","author":"AJ Murphy","year":"2016","unstructured":"Murphy AJ, Michael J, Kammoun HL, Croker BA, Febbraio MA, Masters L, Murphy AJ, Kraakman MJ, Kammoun HL, Dragoljevic D, Lee MKS (2016) IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome article IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome. Cell Metab 23(1):155\u2013164. https:\/\/doi.org\/10.1016\/j.cmet.2015.09.024","journal-title":"Cell Metab"},{"issue":"4","key":"2170_CR32","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","volume":"147","author":"MM Yeh","year":"2014","unstructured":"Yeh MM, Brunt EM (2014) Pathological features of fatty liver disease. Gastroenterology 147(4):754\u2013764. https:\/\/doi.org\/10.1053\/j.gastro.2014.07.056","journal-title":"Gastroenterology"},{"issue":"4","key":"2170_CR33","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-0033-1358523","volume":"33","author":"X Xu","year":"2013","unstructured":"Xu X, So JS, Park JG, Lee AH (2013) Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis 33(4):301\u2013311. https:\/\/doi.org\/10.1055\/s-0033-1358523","journal-title":"Semin Liver Dis"},{"key":"2170_CR34","doi-asserted-by":"publisher","unstructured":"Ortega-Prieto P, Postic C (2019) Carbohydrate sensing through the transcription factor ChREBP. Front Genetics 10:1\u20139. https:\/\/doi.org\/10.3389\/fgene.2019.00472","DOI":"10.3389\/fgene.2019.00472"},{"key":"2170_CR35","doi-asserted-by":"publisher","unstructured":"Rada P, Gonz\u00e1lez-Rodr\u00edguez \u00c1, Garc\u00eda-Monz\u00f3n C, Valverde \u00c1M (2020) Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? .Cell Death Dis 11(9). https:\/\/doi.org\/10.1038\/s41419-020-03003-w","DOI":"10.1038\/s41419-020-03003-w"},{"issue":"27","key":"2170_CR36","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.3748\/wjg.v24.i27.2974","volume":"24","author":"YL Fang","year":"2018","unstructured":"Fang YL, Chen H, Wang CL, Liang L (2018) Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From \u201ctwo hit theory\u201d to \u201cmultiple hit model.\u201d World J Gastroenterol 24(27):2974\u20132983. https:\/\/doi.org\/10.3748\/wjg.v24.i27.2974","journal-title":"World J Gastroenterol"},{"key":"2170_CR37","doi-asserted-by":"publisher","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism: Clinical Exp 65(8):1038\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012","DOI":"10.1016\/j.metabol.2015.12.012"},{"issue":"1","key":"2170_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ncp.10449","volume":"35","author":"MS Mundi","year":"2020","unstructured":"Mundi MS, Velapati S, Patel J, Kellogg TA, Abu Dayyeh BK, Hurt RT (2020) Evolution of NAFLD and its management. Nutr Clin Pract 35(1):72\u201384. https:\/\/doi.org\/10.1002\/ncp.10449","journal-title":"Nutr Clin Pract"},{"issue":"10","key":"2170_CR39","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/oby.22964","volume":"28","author":"MP Moore","year":"2020","unstructured":"Moore MP, Cunningham RP, Dashek RJ, Mucinski JM, Rector RS (2020) A fad too far? Dietary Strategies for the Prevention and Treatment of NAFLD. Obesity 28(10):1843\u20131852. https:\/\/doi.org\/10.1002\/oby.22964","journal-title":"Obesity"},{"issue":"23","key":"2170_CR40","doi-asserted-by":"publisher","first-page":"7366","DOI":"10.3748\/wjg.v20.i23.7366","volume":"20","author":"L Aguirre","year":"2014","unstructured":"Aguirre L, Portillo MP, Hijona E, Bujanda L (2014) Effects of resveratrol and other polyphenols in hepatic steatosis. World J Gastroenterol 20(23):7366\u20137380. https:\/\/doi.org\/10.3748\/wjg.v20.i23.7366","journal-title":"World J Gastroenterol"},{"issue":"3","key":"2170_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.bbrc.2009.01.163","volume":"380","author":"GL Wang","year":"2009","unstructured":"Wang GL, Fu YC, Xu WC, Feng YQ, Fang SR, Zhou XH (2009) Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 380(3):644\u2013649. https:\/\/doi.org\/10.1016\/j.bbrc.2009.01.163","journal-title":"Biochem Biophys Res Commun"},{"issue":"20101018","key":"2170_CR42","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.fct.2013.11.048","volume":"65","author":"CJ Chang","year":"2014","unstructured":"Chang CJ, Liou SS, Tzeng TF, Liu IM (2014) The ethanol extract of Zingiber zerumbet Smith attenuates non-alcoholic fatty liver disease in hamsters fed on high-fat diet. Food Chem Toxicol 65(20101018):33\u201342. https:\/\/doi.org\/10.1016\/j.fct.2013.11.048","journal-title":"Food Chem Toxicol"},{"issue":"3","key":"2170_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1365-2362.2008.02077.x","volume":"39","author":"GV Gnoni","year":"2009","unstructured":"Gnoni GV, Paglialonga G (2009) Resveratrol inhibits fatty acid and triacylglycerol synthesis in rat hepatocytes. Eur J Clin Invest 39(3):211\u2013218. https:\/\/doi.org\/10.1111\/j.1365-2362.2008.02077.x","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"2170_CR44","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.2337\/db05-1188","volume":"55","author":"M Zang","year":"2006","unstructured":"Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55(8):2180\u20132191. https:\/\/doi.org\/10.2337\/db05-1188","journal-title":"Diabetes"},{"key":"2170_CR45","doi-asserted-by":"publisher","unstructured":"Huang Y, Lang H, Chen K, Zhang Y, Gao Y, Ran L, Yi L, Mi M, Zhang Q (2020) Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPAR\u03b1 pathway. In Appl Physiol Nutrition Metabolism 45(3). https:\/\/doi.org\/10.1139\/apnm-2019-0057","DOI":"10.1139\/apnm-2019-0057"},{"issue":"4","key":"2170_CR46","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.cmet.2011.03.009.AMPK","volume":"13","author":"Y Li","year":"2011","unstructured":"Li Y, Xu S, Mihaylova M, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY-J, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M (2011) AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin resistant mice. Cell Metab 13(4):376\u2013388. https:\/\/doi.org\/10.1016\/j.cmet.2011.03.009.AMPK","journal-title":"Cell Metab"},{"key":"2170_CR47","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ejphar.2014.06.017","volume":"740","author":"GZ Dong","year":"2014","unstructured":"Dong GZ, Lee JH, Ki SH, Yang JH, Cho IJ, Kang SH, Zhao RJ, Kim SC, Kim YW (2014) AMPK activation by isorhamnetin protects hepatocytes against oxidative stress and mitochondrial dysfunction. Eur J Pharmacol 740:634\u2013640. https:\/\/doi.org\/10.1016\/j.ejphar.2014.06.017","journal-title":"Eur J Pharmacol"},{"key":"2170_CR48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.fct.2013.08.036","volume":"63","author":"L Li","year":"2014","unstructured":"Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, Weng X (2014) Resveratrol modulates autophagy and NF-\u03baB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol 63:166\u2013173. https:\/\/doi.org\/10.1016\/j.fct.2013.08.036","journal-title":"Food Chem Toxicol"},{"issue":"1\u20132","key":"2170_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11010-016-2807-x","volume":"422","author":"Y Tian","year":"2016","unstructured":"Tian Y, Ma J, Wang W, Zhang L, Xu J, Wang K, Li D (2016) Resveratrol supplement inhibited the NF-\u03baB inflammation pathway through activating AMPK\u03b1-SIRT1 pathway in mice with fatty liver. Mol Cell Biochem 422(1\u20132):75\u201384. https:\/\/doi.org\/10.1007\/s11010-016-2807-x","journal-title":"Mol Cell Biochem"},{"issue":"8","key":"2170_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0183541","volume":"12","author":"S Ding","year":"2017","unstructured":"Ding S, Jiang J, Zhang G, Bu Y, Zhang G, Zhao X (2017) Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. PLoS ONE 12(8):1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0183541","journal-title":"PLoS ONE"},{"issue":"7241","key":"2170_CR51","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/nature07813","volume":"458","author":"C Cant\u00f3","year":"2009","unstructured":"Cant\u00f3 C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, Puigserver P, Auwerx J (2009) AMPK regulates energy expenditure by modulating NAD + metabolism and SIRT1 activity. Nature 458(7241):1056\u20131060. https:\/\/doi.org\/10.1038\/nature07813","journal-title":"Nature"},{"key":"2170_CR52","doi-asserted-by":"publisher","unstructured":"Hosseini H, Teimouri M, Shabani M, Koushki M, Babaei Khorzoughi R, Namvarjah F, Izadi P, Meshkani R (2020) Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway. Int J Biochem Cell Biol 119:105667. https:\/\/doi.org\/10.1016\/j.biocel.2019.105667","DOI":"10.1016\/j.biocel.2019.105667"},{"issue":"8","key":"2170_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu12082435","volume":"12","author":"K Jakubczyk","year":"2020","unstructured":"Jakubczyk K, Skonieczna-\u017cydecka K, Ka\u0142du\u0144ska J, Stachowska E, Gutowska I, Janda K (2020) Effects of resveratrol supplementation in patients with non-alcoholic fatty liver disease\u2014A meta-analysis. Nutrients 12(8):1\u201315. https:\/\/doi.org\/10.3390\/nu12082435","journal-title":"Nutrients"},{"key":"2170_CR54","doi-asserted-by":"publisher","unstructured":"Elgebaly A, Radwan IAI, Aboelnas MM, Ibrahim HH, Eltoomy MFM, Atta AA, Mesalam HA, Sayed AA, Othman AA (2017) Resveratrol supplementation in patients with non-alcoholic fatty liver disease: Systematic review and meta-analysis. J Gastrointestinal Liver Dis 26(1):59\u201367. https:\/\/doi.org\/10.15403\/jgld.2014.1121.261.ely","DOI":"10.15403\/jgld.2014.1121.261.ely"},{"issue":"2","key":"2170_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11154-019-09494-z","volume":"20","author":"S Asgary","year":"2019","unstructured":"Asgary S, Karimi R, Momtaz S, Naseri R, Farzaei MH (2019) Effect of resveratrol on metabolic syndrome components: a systematic review and meta-analysis. Rev Endocr Metab Disord 20(2):173\u2013186. https:\/\/doi.org\/10.1007\/s11154-019-09494-z","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"2170_CR56","doi-asserted-by":"publisher","first-page":"797","DOI":"10.4103\/1735-1995.168405","volume":"20","author":"F Faghihzadeh","year":"2015","unstructured":"Faghihzadeh F, Hekmatdoost A, Adibi P (2015) Resveratrol and liver: A systematic review. Journal of Research in Medical Sciences 20(8):797\u2013810. https:\/\/doi.org\/10.4103\/1735-1995.168405","journal-title":"Journal of Research in Medical Sciences"},{"issue":"3","key":"2170_CR57","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/10408398.2018.1529654","volume":"60","author":"R Tabrizi","year":"2020","unstructured":"Tabrizi R, Tamtaji OR, Lankarani KB, Akbari M, Dadgostar E, Dabbaghmanesh MH, Kolahdooz F, Shamshirian A, Momen-Heravi M, Asemi Z (2020) The effects of resveratrol intake on weight loss: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 60(3):375\u2013390. https:\/\/doi.org\/10.1080\/10408398.2018.1529654","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"2170_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu11010143","volume":"11","author":"M Springer","year":"2019","unstructured":"Springer M, Moco S (2019) Resveratrol and its human metabolites\u2014effects on metabolic health and obesity. Nutrients 11(1):1\u201317. https:\/\/doi.org\/10.3390\/nu11010143","journal-title":"Nutrients"},{"key":"2170_CR59","doi-asserted-by":"publisher","unstructured":"Hyrsova L, Vanduchova A, Dusek J, Smutny T, Carazo A, Maresova V, Trejtnar F, Barta P, Anzenbacher P, Dvorak Z, Pavek P (2019) Trans-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors. Toxicology Lett 300:81\u201391. https:\/\/doi.org\/10.1016\/j.toxlet.2018.10.028","DOI":"10.1016\/j.toxlet.2018.10.028"},{"key":"2170_CR60","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.foodchem.2017.06.040","volume":"237","author":"L Basheer","year":"2017","unstructured":"Basheer L, Schultz K, Guttman Y, Kerem Z (2017) In silico and in vitro inhibition of cytochrome P450 3A by synthetic stilbenoids. Food Chem 237:895\u2013903. https:\/\/doi.org\/10.1016\/j.foodchem.2017.06.040","journal-title":"Food Chem"},{"issue":"9","key":"2170_CR61","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1158\/1940-6207.CAPR-09-0155","volume":"3","author":"HHS Chow","year":"2010","unstructured":"Chow HHS, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS (2010) Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res 3(9):1168\u20131175. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-09-0155","journal-title":"Cancer Prev Res"},{"issue":"1","key":"2170_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1006\/bbrc.1999.1152","volume":"262","author":"YJ Chun","year":"1999","unstructured":"Chun YJ, Kim MY, Guengerich FP (1999) Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262(1):20\u201324. https:\/\/doi.org\/10.1006\/bbrc.1999.1152","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2170_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu8030167","volume":"8","author":"Y Li","year":"2016","unstructured":"Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, Liu H, Yin Y (2016) Quercetin, inflammation and immunity. Nutrients 8(3):1\u201314. https:\/\/doi.org\/10.3390\/nu8030167","journal-title":"Nutrients"},{"issue":"1","key":"2170_CR64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3892\/br.2012.27","volume":"1","author":"X Li","year":"2012","unstructured":"Li X, Wang R, Zhou N, Wang X, Liu Q, Bai Y, Bai Y, Liu Z, Yang H, Zou J, Wang H, Shi T (2012) Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model. Biomedical Reports 1(1):71\u201376. https:\/\/doi.org\/10.3892\/br.2012.27","journal-title":"Biomedical Reports"},{"issue":"4","key":"2170_CR65","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1515\/jbcpp-2020-0423","volume":"32","author":"JNS Al-maamari","year":"2021","unstructured":"Al-maamari JNS, Rahmadi M, Panggono SM (2021) The effects of quercetin on the expression of SREBP- 1c mRNA in high-fat diet-induced NAFLD in mice. J Basic Clin Physiol Pharmacol 32(4):637\u2013644. https:\/\/doi.org\/10.1515\/jbcpp-2020-0423","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"2","key":"2170_CR66","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.tiv.2013.01.014","volume":"27","author":"S Vidyashankar","year":"2013","unstructured":"Vidyashankar S, Sandeep Varma R, Patki PS (2013) Quercetin ameliorate insulin resistance and up-regulates cellular antioxidants during oleic acid induced hepatic steatosis in HepG2 cells. Toxicol In Vitro 27(2):945\u2013953. https:\/\/doi.org\/10.1016\/j.tiv.2013.01.014","journal-title":"Toxicol In Vitro"},{"issue":"1","key":"2170_CR67","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/bit.27557","volume":"118","author":"M Gori","year":"2021","unstructured":"Gori M, Giannitelli SM, Zancla A, Mozetic P, Trombetta M, Merendino N, Rainer A (2021) Quercetin and hydroxytyrosol as modulators of hepatic steatosis: A NAFLD-on-a-chip study. Biotechnol Bioeng 118(1):142\u2013152. https:\/\/doi.org\/10.1002\/bit.27557","journal-title":"Biotechnol Bioeng"},{"issue":"12","key":"2170_CR68","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1002\/ptr.6486","volume":"33","author":"H Yang","year":"2019","unstructured":"Yang H, Yang T, Heng C, Zhou Y, Jiang Z, Qian X, Du L, Mao S, Yin X, Lu Q (2019) Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db\/db mice. Phytother Res 33(12):3140\u20133152. https:\/\/doi.org\/10.1002\/ptr.6486","journal-title":"Phytother Res"},{"issue":"4","key":"2170_CR69","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/mnfr.201000392","volume":"55","author":"M Kobori","year":"2011","unstructured":"Kobori M, Masumoto S, Akimoto Y, Oike H (2011) Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57\/BL6J mice. Mol Nutr Food Res 55(4):530\u2013540. https:\/\/doi.org\/10.1002\/mnfr.201000392","journal-title":"Mol Nutr Food Res"},{"issue":"1","key":"2170_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12986-015-0030-5","volume":"12","author":"CS Kim","year":"2015","unstructured":"Kim CS, Kwon Y, Choe SY, Hong SM, Yoo H, Goto T, Kawada T, Choi HS, Joe Y, Chung HT, Yu R (2015) Quercetin reduces obesity-induced hepatosteatosis by enhancing mitochondrial oxidative metabolism via heme oxygenase-1. Nutr Metab 12(1):1\u20139. https:\/\/doi.org\/10.1186\/s12986-015-0030-5","journal-title":"Nutr Metab"},{"key":"2170_CR71","doi-asserted-by":"publisher","unstructured":"Liu L, Gao C, Yao P, Gong Z (2015) Quercetin alleviates high-fat diet-induced oxidized low-density lipoprotein accumulation in the liver: Implication for autophagy regulation. Biomed Res Int 2015. https:\/\/doi.org\/10.1155\/2015\/607531","DOI":"10.1155\/2015\/607531"},{"issue":"1","key":"2170_CR72","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ptr.4687","volume":"27","author":"CH Jung","year":"2012","unstructured":"Jung CH, Cho I, Ahn J, Jeon TI, Ha TY (2012) Quercetin reduces high-fat diet-induced fat accumulation in the liver by regulating lipid metabolism genes. Phytother Res 27(1):139\u2013143. https:\/\/doi.org\/10.1002\/ptr.4687","journal-title":"Phytother Res"},{"key":"2170_CR73","doi-asserted-by":"publisher","unstructured":"Zhu X, Xiong T, Liu P, Guo X, Xiao L, Zhou F, Tang Y, Yao P (2018) Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a\/XBP1s pathway. Food Chem Toxicol 114:52\u201360. https:\/\/doi.org\/10.1016\/j.fct.2018.02.019","DOI":"10.1016\/j.fct.2018.02.019"},{"key":"2170_CR74","doi-asserted-by":"publisher","unstructured":"Shabalala SC, Dludla PV, Mabasa L, Kappo AP, Basson AK, Pheiffer C, Johnson R (2020) The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. Biomed Pharmacoth 131. https:\/\/doi.org\/10.1016\/j.biopha.2020.110785","DOI":"10.1016\/j.biopha.2020.110785"},{"key":"2170_CR75","doi-asserted-by":"publisher","unstructured":"Porras D, Nistal E, Mart\u00ednez-Fl\u00f3rez S, Pisonero-Vaquero S, Olcoz JL, Jover R, Gonz\u00e1lez-Gallego J, Garc\u00eda-Mediavilla MV, S\u00e1nchez-Campos S (2017) Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radical Biol Med 102:188\u2013202. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2016.11.037","DOI":"10.1016\/j.freeradbiomed.2016.11.037"},{"issue":"12","key":"2170_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms19124126","volume":"19","author":"G Qin","year":"2018","unstructured":"Qin G, Ma J, Huang Q, Yin H, Han J, Li M, Deng Y, Wang B, Hassan W, Shang J (2018) Isoquercetin improves hepatic lipid accumulation by activating AMPK pathway and suppressing TGF-\u03b2 signaling on an HFD-induced nonalcoholic fatty liver disease rat model. Int J Mol Sci 19(12):1\u201315. https:\/\/doi.org\/10.3390\/ijms19124126","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2170_CR77","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1108\/NFS-10-2019-0321","volume":"50","author":"M Hosseinikia","year":"2020","unstructured":"Hosseinikia M, Oubari F, Hosseinkia R, Tabeshfar Z, Salehi MG, Mousavian Z, Abbasi M, Samadi M, Pasdar Y (2020) Quercetin supplementation in non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. Nutrition and Food Science 50(6):1279\u20131293. https:\/\/doi.org\/10.1108\/NFS-10-2019-0321","journal-title":"Nutrition and Food Science"},{"issue":"2","key":"2170_CR78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/09637486.2019.1627515","volume":"71","author":"Q Ou","year":"2020","unstructured":"Ou Q, Zheng Z, Zhao Y, Lin W (2020) Impact of quercetin on systemic levels of inflammation: a meta-analysis of randomised controlled human trials. Int J Food Sci Nutr 71(2):152\u2013163. https:\/\/doi.org\/10.1080\/09637486.2019.1627515","journal-title":"Int J Food Sci Nutr"},{"issue":"4","key":"2170_CR79","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/10408398.2014.948609","volume":"57","author":"A Sahebkar","year":"2017","unstructured":"Sahebkar A (2017) Effects of quercetin supplementation on lipid profile: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 57(4):666\u2013676. https:\/\/doi.org\/10.1080\/10408398.2014.948609","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"11","key":"2170_CR80","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1080\/10408398.2019.1604491","volume":"60","author":"R Tabrizi","year":"2020","unstructured":"Tabrizi R, Tamtaji OR, Mirhosseini N, Lankarani KB, Akbari M, Heydari ST, Dadgostar E, Asemi Z (2020) The effects of quercetin supplementation on lipid profiles and inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr 60(11):1855\u20131868. https:\/\/doi.org\/10.1080\/10408398.2019.1604491","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"8","key":"2170_CR81","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/nutrit\/nuz071","volume":"78","author":"H Huang","year":"2020","unstructured":"Huang H, Liao D, Dong Y, Pu R (2020) Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: A systematic review and meta-analysis. Nutr Rev 78(8):615\u2013626. https:\/\/doi.org\/10.1093\/nutrit\/nuz071","journal-title":"Nutr Rev"},{"issue":"3","key":"2170_CR82","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jnutbio.2014.10.008","volume":"26","author":"Y Guo","year":"2015","unstructured":"Guo Y, Bruno RS (2015) Endogenous and exogenous mediators of quercetin bioavailability. J Nutr Biochem 26(3):201\u2013210. https:\/\/doi.org\/10.1016\/j.jnutbio.2014.10.008","journal-title":"J Nutr Biochem"},{"issue":"6","key":"2170_CR83","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s11095-005-4584-1","volume":"22","author":"X Chen","year":"2005","unstructured":"Chen X, Yin OQP, Zuo Z, Chow MSS (2005) Pharmacokinetics and modeling of quercetin and metabolites. Pharm Res 22(6):892\u2013901. https:\/\/doi.org\/10.1007\/s11095-005-4584-1","journal-title":"Pharm Res"},{"key":"2170_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2020.110984","volume":"133","author":"H Yi","year":"2021","unstructured":"Yi H, Peng H, Wu X, Xu X, Kuang T, Zhang J, Du L, Fan G (2021) The therapeutic effects and mechanisms of quercetin on metabolic diseases: pharmacological data and clinical evidence. Oxid Med Cell Longev 133:1\u201316. https:\/\/doi.org\/10.1016\/j.biopha.2020.110984","journal-title":"Oxid Med Cell Longev"},{"issue":"8","key":"2170_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu12082306","volume":"12","author":"V Mohos","year":"2020","unstructured":"Mohos V, Flisz\u00e1r-Ny\u00fal E, Ungv\u00e1ri O, Kuffa K, Needs PW, Kroon PA, Telbisz \u00c1, \u00d6zvegy-Laczka C, Po\u00f3r M (2020) Inhibitory effects of quercetin and its main methyl, sulfate, and glucuronic acid conjugates on cytochrome p450 enzymes, and on OATP, BCRP and MRP2 transporters. Nutrients 12(8):1\u201316. https:\/\/doi.org\/10.3390\/nu12082306","journal-title":"Nutrients"},{"key":"2170_CR86","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jep.2015.06.011","volume":"173","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhao JJ, Xu J, Feng F, Qu W (2015) Medicinal uses, phytochemistry and pharmacology of the genus Uncaria. J Ethnopharmacol 173:48\u201380. https:\/\/doi.org\/10.1016\/j.jep.2015.06.011","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"2170_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-29044-y","volume":"8","author":"LCC Araujo","year":"2018","unstructured":"Araujo LCC, Feitosa KB, Murata GM, Furigo IC, Teixeira SA, Lucena CF, Ribeiro LM, Muscar\u00e1 MN, Costa SKP, Donato J, Bordin S, Curi R, Carvalho CRO (2018) Uncaria tomentosa improves insulin sensitivity and inflammation in experimental NAFLD. Sci Rep 8(1):1\u201314. https:\/\/doi.org\/10.1038\/s41598-018-29044-y","journal-title":"Sci Rep"},{"issue":"1","key":"2170_CR88","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jep.2011.06.021","volume":"137","author":"A Domingues","year":"2011","unstructured":"Domingues A, Sartori A, Golim MA, Valente LMM, Da Rosa LC, Ishikawa LLW, Siani AC, Viero RM (2011) Prevention of experimental diabetes by Uncaria tomentosa extract: Th2 polarization, regulatory T cell preservation or both? J Ethnopharmacol 137(1):635\u2013642. https:\/\/doi.org\/10.1016\/j.jep.2011.06.021","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"2170_CR89","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jep.2012.07.015","volume":"143","author":"R Rojas-Duran","year":"2012","unstructured":"Rojas-Duran R, Gonz\u00e1lez-Aspajo G, Ruiz-Martel C, Bourdy G, Doroteo-Ortega VH, Alban-Castillo J, Robert G, Auberger P, Deharo E (2012) Anti-inflammatory activity of Mitraphylline isolated from Uncaria tomentosa bark. J Ethnopharmacol 143(3):801\u2013804. https:\/\/doi.org\/10.1016\/j.jep.2012.07.015","journal-title":"J Ethnopharmacol"},{"key":"2170_CR90","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jep.2015.05.002","volume":"170","author":"S Montserrat-De La Paz","year":"2015","unstructured":"Montserrat-De La Paz S, De La Puerta R, Fernandez-Arche A, Quilez AM, Muriana FJG, Garcia-Gimenez MD, Bermudez B (2015) Pharmacological effects of mitraphylline from Uncaria tomentosa in primary human monocytes: Skew toward M2 macrophages. J Ethnopharmacol 170:128\u2013135. https:\/\/doi.org\/10.1016\/j.jep.2015.05.002","journal-title":"J Ethnopharmacol"},{"issue":"3","key":"2170_CR91","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0378-8741(97)00067-6","volume":"57","author":"A Santa Maria","year":"1997","unstructured":"Santa Maria A, Lopez A, Diaz MM, Alb\u00e1n J, Gal\u00e1n De Mera A, Vicente Orellana JA, Pozuelo JM (1997) Evaluation of the toxicity of Uncaria tomentosa by bioassays in vitro. J Ethnopharmacol 57(3):183\u2013187. https:\/\/doi.org\/10.1016\/S0378-8741(97)00067-6","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"2170_CR92","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1078\/0944-7113-00045","volume":"8","author":"Y Sheng","year":"2001","unstructured":"Sheng Y, Li L, Holmgren K, Pero RW (2001) DNA repair enhancement of aqueous extracts of Uncaria tomentosa in a human volunteer study. Phytomedicine 8(4):275\u2013282","journal-title":"Phytomedicine"},{"issue":"4","key":"2170_CR93","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1078\/0944-7113-00046","volume":"8","author":"S Lamm","year":"2001","unstructured":"Lamm S, Sheng Y, Pero RW (2001) Persistent response to pneumococcal vaccine in individuals supplemented with a novel water soluble extract of Uncaria tomentosa, C-Med-100\u00ae. Phytomedicine 8(4):267\u2013274. https:\/\/doi.org\/10.1078\/0944-7113-00046","journal-title":"Phytomedicine"},{"issue":"4","key":"2170_CR94","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0944-7113(00)80044-6","volume":"7","author":"JW Budzinski","year":"2000","unstructured":"Budzinski JW, Foster BC, Vandenhoek S, Arnason JT (2000) An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 7(4):273\u2013282. https:\/\/doi.org\/10.1016\/S0944-7113(00)80044-6","journal-title":"Phytomedicine"},{"issue":"10","key":"2170_CR95","first-page":"736","volume":"3","author":"FB Apea-Bah","year":"2009","unstructured":"Apea-Bah FB, Hanafi M, Dewi RT, Fajriah S, Darwaman A, Artanti N, Lotulung P, Ngadymang P, Minarti B (2009) Assessment of the DPPH and \u03b1-glucosidase inhibitory potential of gambier and qualitative identification of major bioactive compound. Journal of Medicinal Plants Research 3(10):736\u2013757","journal-title":"Journal of Medicinal Plants Research"},{"key":"2170_CR96","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.fitote.2013.07.005","volume":"90","author":"ZW Wang","year":"2013","unstructured":"Wang ZW, Wang JS, Luo J, Kong LY (2013) \u03b1-Glucosidase inhibitory triterpenoids from the stem barks of Uncaria laevigata. Fitoterapia 90:30\u201337. https:\/\/doi.org\/10.1016\/j.fitote.2013.07.005","journal-title":"Fitoterapia"},{"issue":"1","key":"2170_CR97","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0891-5849(00)00327-0","volume":"29","author":"M Sandoval","year":"2000","unstructured":"Sandoval M, Charbonnet RM, Okuhama NN, Roberts J, Krenova K, Trentacosti AM, Miller MJS et al (2000) Cat\u2019s claw inhibits TNFa production and scavenges free. Free Radical Biol Med 29(1):71\u201378","journal-title":"Free Radical Biol Med"},{"issue":"5","key":"2170_CR98","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1089\/jmf.2010.1128","volume":"13","author":"J Kim","year":"2010","unstructured":"Kim J, Park SY, Lee SJ, Kim Y (2010) Uncaria rhynchophylla inhibits the production of nitric oxide and interleukin-1b through blocking nuclear factor jB, Akt, and mitogen-activated protein kinase activation in macrophages. J Med Food 13(5):1133\u20131140","journal-title":"J Med Food"},{"key":"2170_CR99","doi-asserted-by":"publisher","unstructured":"Federico A, Dallio M, Loguercio C (2017) Silymarin\/Silybin and chronic liver disease: a marriage of many years. Molecules 22(2). https:\/\/doi.org\/10.3390\/molecules22020191","DOI":"10.3390\/molecules22020191"},{"issue":"1","key":"2170_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-40105-8","volume":"9","author":"S Lama","year":"2019","unstructured":"Lama S, Vanacore D, Diano N, Nicolucci C, Errico S, Dallio M, Federico A, Loguercio C, Stiuso P (2019) Ameliorative effect of Silybin on bisphenol A induced oxidative stress, cell proliferation and steroid hormones oxidation in HepG2 cell cultures. Sci Rep 9(1):1\u201310. https:\/\/doi.org\/10.1038\/s41598-019-40105-8","journal-title":"Sci Rep"},{"issue":"4","key":"2170_CR101","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1742-7843.2007.00116.x.Silymarin","volume":"101","author":"Z Song","year":"2007","unstructured":"Song Z, Song M, Lee DYW, Liu Y, Deaciuc IV, McClain CJ (2007) Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation. Basic Clin Pharmacol Toxicol 101(4):262\u2013268. https:\/\/doi.org\/10.1111\/j.1742-7843.2007.00116.x.Silymarin","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7\u20138","key":"2170_CR102","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.phymed.2015.05.053","volume":"22","author":"CY Hsiang","year":"2015","unstructured":"Hsiang CY, Lin LJ, Kao ST, Lo HY, Chou ST, Ho TY (2015) Glycyrrhizin, silymarin, and ursodeoxycholic acid regulate a common hepatoprotective pathway in HepG2 cells. Phytomedicine 22(7\u20138):768\u2013777. https:\/\/doi.org\/10.1016\/j.phymed.2015.05.053","journal-title":"Phytomedicine"},{"issue":"2","key":"2170_CR103","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1096\/fj.201700602R","volume":"32","author":"B Zhang","year":"2018","unstructured":"Zhang B, Xu D, She L, Wang Z, Yang N, Sun R, Zhang Y, Yan C, Wei Q, Aa J, Liu B, Wang G, Xie Y (2018) Silybin inhibits NLRP3 inflammasome assembly through the NAD+\/SIRT2 pathway in mice with nonalcoholic fatty liver disease. FASEB J 32(2):757\u2013767. https:\/\/doi.org\/10.1096\/fj.201700602R","journal-title":"FASEB J"},{"issue":"3","key":"2170_CR104","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.intimp.2013.08.019","volume":"17","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Hai J, Cao M, Zhang Y, Pei S, Wang J, Zhang Q (2013) Silibinin ameliorates steatosis and insulin resistance during non-alcoholic fatty liver disease development partly through targeting IRS-1\/PI3K\/Akt pathway. Int Immunopharmacol 17(3):714\u2013720. https:\/\/doi.org\/10.1016\/j.intimp.2013.08.019","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"2170_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jfbc.13194","volume":"44","author":"E Sahin","year":"2020","unstructured":"Sahin E, Bagci R, Bektur Aykanat NE, Kacar S, Sahinturk V (2020) Silymarin attenuated nonalcoholic fatty liver disease through the regulation of endoplasmic reticulum stress proteins GRP78 and XBP-1 in mice. J Food Biochem 44(6):1\u201311. https:\/\/doi.org\/10.1111\/jfbc.13194","journal-title":"J Food Biochem"},{"issue":"12","key":"2170_CR106","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1007\/s10620-018-5268-0","volume":"63","author":"Q Ou","year":"2018","unstructured":"Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, Wu X (2018) Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the Nf-\u03baB pathway. Dig Dis Sci 63(12):3398\u20133408. https:\/\/doi.org\/10.1007\/s10620-018-5268-0","journal-title":"Dig Dis Sci"},{"issue":"4","key":"2170_CR107","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.dld.2011.11.010","volume":"44","author":"F Salamone","year":"2012","unstructured":"Salamone F, Galvano F, Marino A, Paternostro C, Tibullo D, Bucchieri F, Mangiameli A, Parola M, Bugianesi E, Li Volti G (2012) Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis. Dig Liver Dis 44(4):334\u2013342. https:\/\/doi.org\/10.1016\/j.dld.2011.11.010","journal-title":"Dig Liver Dis"},{"issue":"6","key":"2170_CR108","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.trsl.2011.12.003","volume":"159","author":"F Salamone","year":"2012","unstructured":"Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G (2012) Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res 159(6):477\u2013486. https:\/\/doi.org\/10.1016\/j.trsl.2011.12.003","journal-title":"Transl Res"},{"issue":"2","key":"2170_CR109","first-page":"1073","volume":"8","author":"X Ni","year":"2016","unstructured":"Ni X, Wang H (2016) Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). American Journal of Translational Research 8(2):1073\u20131081","journal-title":"American Journal of Translational Research"},{"key":"2170_CR110","doi-asserted-by":"publisher","unstructured":"Salomone F, Barbagallo I, Godos J, Lembo V, Currenti W, Cin\u00e0 D, Avola R, D\u2019Orazio N, Morisco F, Galvano F, Li Volti G (2017) Silibinin restores NAD+ levels and induces the SIRT1\/AMPK pathway in non-alcoholic fatty liver. Nutrients 9(10). https:\/\/doi.org\/10.3390\/nu9101086","DOI":"10.3390\/nu9101086"},{"key":"2170_CR111","doi-asserted-by":"publisher","unstructured":"Sun R, Xu D, Wei Q, Zhang B, Aa J, Wang G, Xie Y (2020) Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacoth 123:109721. https:\/\/doi.org\/10.1016\/j.biopha.2019.109721","DOI":"10.1016\/j.biopha.2019.109721"},{"issue":"3","key":"2170_CR112","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1590\/1414-431X20122551","volume":"46","author":"J Yao","year":"2013","unstructured":"Yao J, Zhi M, Gao X, Hu P, Li C, Yang X (2013) Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res 46(3):270\u2013277. https:\/\/doi.org\/10.1590\/1414-431X20122551","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"2170_CR113","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3892\/ijmm.2012.1029","volume":"30","author":"M Kim","year":"2012","unstructured":"Kim M, Yang SG, Kim JM, Lee JW, Kim YS, Lee JI (2012) Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: Analysis of isolated hepatic stellate cells. Int J Mol Med 30(3):473\u2013479. https:\/\/doi.org\/10.3892\/ijmm.2012.1029","journal-title":"Int J Mol Med"},{"key":"2170_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2020.111092","volume":"83","author":"G Kalopitas","year":"2021","unstructured":"Kalopitas G, Antza C, Doundoulakis I, Siargkas A, Kouroumalis E, Germanidis G, Samara M, Chourdakis M (2021) The impact of silymarin in individuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Nutrition 83:111092. https:\/\/doi.org\/10.1016\/j.nut.2020.111092","journal-title":"Nutrition"},{"key":"2170_CR115","doi-asserted-by":"publisher","unstructured":"Zhong S, Fan Y, Yan Q, Fan X, Wu B, Han Y, Zhang Y, Chen Y, Zhang H, Niu J (2017) The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: a meta-analysis (PRISMA) of randomized control trials. Medicine (United States) 96(49). https:\/\/doi.org\/10.1097\/MD.0000000000009061","DOI":"10.1097\/MD.0000000000009061"},{"key":"2170_CR116","doi-asserted-by":"publisher","unstructured":"Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic A (2016) Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Res 2016. https:\/\/doi.org\/10.1155\/2016\/5147468","DOI":"10.1155\/2016\/5147468"},{"issue":"August","key":"2170_CR117","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ctim.2018.08.010","volume":"41","author":"A Hadi","year":"2018","unstructured":"Hadi A, Pourmasoumi M, Mohammadi H, Symonds M, Miraghajani M (2018) The effects of silymarin supplementation on metabolic status and oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Complement Ther Med 41(August):311\u2013319. https:\/\/doi.org\/10.1016\/j.ctim.2018.08.010","journal-title":"Complement Ther Med"},{"issue":"40","key":"2170_CR118","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022249","volume":"99","author":"F Xiao","year":"2020","unstructured":"Xiao F, Gao F, Zhou S, Wang L (2020) The therapeutic effects of silymarin for patients with glucose\/lipid metabolic dysfunction: A meta-analysis. Medicine 99(40):e22249. https:\/\/doi.org\/10.1097\/MD.0000000000022249","journal-title":"Medicine"},{"issue":"11","key":"2170_CR119","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules24112155","volume":"24","author":"A Di Costanzo","year":"2019","unstructured":"Di Costanzo A, Angelico R (2019) Formulation strategies for enhancing the bioavailability of silymarin: The state of the art. Molecules 24(11):1\u201329. https:\/\/doi.org\/10.3390\/molecules24112155","journal-title":"Molecules"},{"issue":"6","key":"2170_CR120","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1002\/ptr.6361","volume":"33","author":"V Soleimani","year":"2019","unstructured":"Soleimani V, Delghandi PS, Moallem SA, Karimi G (2019) Safety and toxicity of silymarin, the major constituent of milk thistle extract: an updated review. Phytother Res 33(6):1627\u20131638. https:\/\/doi.org\/10.1002\/ptr.6361","journal-title":"Phytother Res"},{"issue":"10","key":"2170_CR121","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/ejcn.2010.136","volume":"64","author":"C Hutchinson","year":"2010","unstructured":"Hutchinson C, Bomford A, Geissler CA (2010) The iron-chelating potential of silybin in patients with hereditary haemochromatosis. Eur J Clin Nutr 64(10):1239\u20131241. https:\/\/doi.org\/10.1038\/ejcn.2010.136","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"2170_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-014-0087-x","volume":"21","author":"T Wei","year":"2014","unstructured":"Wei T, Xiong FF, Wang SD, Wang K, Zhang YY, Zhang QH (2014) Flavonoid ingredients of Ginkgo biloba leaf extract regulate lipid metabolism through Sp1-mediated carnitine palmitoyltranferase 1A up-regulation. J Biomed Sci 21(1):1\u201311. https:\/\/doi.org\/10.1186\/s12929-014-0087-x","journal-title":"J Biomed Sci"},{"issue":"10","key":"2170_CR123","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1751-2980.2012.00627.x","volume":"13","author":"SD Wang","year":"2012","unstructured":"Wang SD, Xie ZQ, Chen J, Wang K, Wei T, Zhao AH, Zhang QH (2012) Inhibitory effect of ginkgo biloba extract on fatty liver: Regulation of carnitine palmitoyltransferase 1a and fatty acid metabolism. J Dig Dis 13(10):525\u2013535. https:\/\/doi.org\/10.1111\/j.1751-2980.2012.00627.x","journal-title":"J Dig Dis"},{"key":"2170_CR124","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2147\/JIR.S302934","volume":"14","author":"L Li","year":"2021","unstructured":"Li L, Yang L, Yang F, Zhao XL, Xue S, Gong FH (2021) Ginkgo biloba extract 50 (Gbe50) ameliorates insulin resistance, hepatic steatosis and liver injury in high fat diet-fed mice. J Inflamm Res 14:1959\u20131971. https:\/\/doi.org\/10.2147\/JIR.S302934","journal-title":"J Inflamm Res"},{"key":"2170_CR125","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ijbiomac.2015.05.054","volume":"80","author":"Z Yan","year":"2015","unstructured":"Yan Z, Fan R, Yin S, Zhao X, Liu J, Li L, Zhang W, Ge L (2015) Protective effects of Ginkgo biloba leaf polysaccharide on nonalcoholic fatty liver disease and its mechanisms. Int J Biol Macromol 80:573\u2013580. https:\/\/doi.org\/10.1016\/j.ijbiomac.2015.05.054","journal-title":"Int J Biol Macromol"},{"key":"2170_CR126","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.biopha.2017.01.114","volume":"88","author":"HS Jeong","year":"2017","unstructured":"Jeong HS, Kim KH, Lee IS, Park JY, Kim Y, Kim KS, Jang HJ (2017) Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice. Biomed Pharmacother 88:625\u2013634. https:\/\/doi.org\/10.1016\/j.biopha.2017.01.114","journal-title":"Biomed Pharmacother"},{"issue":"July","key":"2170_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2020.152599","volume":"445","author":"Y Yang","year":"2020","unstructured":"Yang Y, Chen J, Gao Q, Shan X, Wang J, Lv Z (2020) Study on the attenuated effect of Ginkgolide B on ferroptosis in high fat diet induced nonalcoholic fatty liver disease. Toxicology 445(July):152599. https:\/\/doi.org\/10.1016\/j.tox.2020.152599","journal-title":"Toxicology"},{"key":"2170_CR128","doi-asserted-by":"publisher","unstructured":"Wanwimolruk S, Prachayasittikul V (2014) Cytochrome P450 enzyme mediated herbal drug interactions (part 1). EXCLI J 13:347\u2013391. https:\/\/doi.org\/10.17877\/DE290R-15628","DOI":"10.17877\/DE290R-15628"},{"issue":"7","key":"2170_CR129","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/mnfr.200700098","volume":"52","author":"KM Bone","year":"2008","unstructured":"Bone KM (2008) Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: What is the evidence? Mol Nutr Food Res 52(7):764\u2013771. https:\/\/doi.org\/10.1002\/mnfr.200700098","journal-title":"Mol Nutr Food Res"},{"issue":"12","key":"2170_CR130","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1345\/aph.10031","volume":"34","author":"LPJ Vaes","year":"2000","unstructured":"Vaes LPJ, Chyka PA (2000) Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: Nature of the evidence. Ann Pharmacother 34(12):1478\u20131482. https:\/\/doi.org\/10.1345\/aph.10031","journal-title":"Ann Pharmacother"},{"key":"2170_CR131","doi-asserted-by":"crossref","unstructured":"Kahraman C, Arituluk ZC, Cankaya IIT (2020) The clinical importance of herb-drug interactions and toxicological risks of plants and herbal products. In Med Toxicol. https:\/\/www.intechopen.com\/books\/advanced-biometric-technologies\/liveness-detection-in-biometrics","DOI":"10.5772\/intechopen.92040"},{"key":"2170_CR132","doi-asserted-by":"publisher","unstructured":"L\u00fcde S, Vecchio S, S S-T, A D, H M, S V, B J, D M, L VGF, K H, E DSN, C DL, P R, H K, A C (2016) Adverse effects of plant food supplements and plants consumed as food: results from the Poisons Centres-Based PlantLIBRA Study. Phytotherapy Res 30(6):988\u2013996. http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id=L608880617%0Ahttp:\/\/dx.doi.org\/https:\/\/doi.org\/10.1002\/ptr.5604","DOI":"10.1002\/ptr.5604"},{"issue":"9","key":"2170_CR133","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1875-5364(19)30081-0","volume":"17","author":"YY Li","year":"2019","unstructured":"Li YY, Lu XY, Sun JL, Wang QQ, Zhang YD, Zhang JB, Fan XH (2019) Potential hepatic and renal toxicity induced by the biflavonoids from Ginkgo biloba. Chin J Nat Med 17(9):672\u2013681. https:\/\/doi.org\/10.1016\/S1875-5364(19)30081-0","journal-title":"Chin J Nat Med"},{"issue":"2","key":"2170_CR134","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jgr.2019.09.004","volume":"44","author":"M Park","year":"2020","unstructured":"Park M, Yoo JH, Lee YS, Park EJ, Lee HJ (2020) Ameliorative effects of black ginseng on nonalcoholic fatty liver disease in free fatty acid\u2013induced HepG2 cells and high-fat\/high-fructose diet-fed mice. J Ginseng Res 44(2):350\u2013361. https:\/\/doi.org\/10.1016\/j.jgr.2019.09.004","journal-title":"J Ginseng Res"},{"issue":"5","key":"2170_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18051063","volume":"18","author":"Q Huang","year":"2017","unstructured":"Huang Q, Wang T, Yang L, Wang HY (2017) Ginsenoside Rb2 alleviates hepatic lipid accumulation by restoring autophagy via induction of sirt1 and activation of AMPK. Int J Mol Sci 18(5):1\u201315. https:\/\/doi.org\/10.3390\/ijms18051063","journal-title":"Int J Mol Sci"},{"key":"2170_CR136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep41144","volume":"7","author":"XJ Chen","year":"2017","unstructured":"Chen XJ, Liu WJ, Wen ML, Liang H, Wu SM, Zhu YZ, Zhao JY, Dong XQ, Li MG, Bian L, Zou CG, Ma LQ (2017) Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats. Sci Rep 7:1\u201311. https:\/\/doi.org\/10.1038\/srep41144","journal-title":"Sci Rep"},{"issue":"3","key":"2170_CR137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu13030856","volume":"13","author":"F Wang","year":"2021","unstructured":"Wang F, Park JS, Ma Y, Ma H, Lee YJ, Lee GR, Yoo HS, Roh YS, Hong JT (2021) Ginseng saponin enriched in rh1 and rg2 ameliorates nonalcoholic fatty liver disease by inhibiting inflammasome activation. Nutrients 13(3):1\u201317. https:\/\/doi.org\/10.3390\/nu13030856","journal-title":"Nutrients"},{"issue":"3","key":"2170_CR138","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1590\/s0004-28032014000300016","volume":"51","author":"MIRANDA-HENRIQUES, M. S. de, DINIZ,","year":"2014","unstructured":"MIRANDA-HENRIQUES, M. S. de, DINIZ, M. de F. F. de M., & ARA\u00daJO, M. S. T. de. (2014) GINSENG, GREEN TEA OR FIBRATE: valid options for nonalcoholic steatohepatitis prevention? Arq Gastroenterol 51(3):255\u2013260. https:\/\/doi.org\/10.1590\/s0004-28032014000300016","journal-title":"Arq Gastroenterol"},{"key":"2170_CR139","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.fct.2013.01.022","volume":"55","author":"SH Hong","year":"2013","unstructured":"Hong SH, Suk KT, Choi SH, Lee JW, Sung HT, Kim CH, Kim EJ, Kim MJ, Han SH, Kim MY, Baik SK, Kim DJ, Lee GJ, Lee S, kyu, Park, S. H., & Ryu, O. H. (2013) Anti-oxidant and natural killer cell activity of Korean red ginseng (Panax ginseng) and urushiol (Rhus vernicifera Stokes) on non-alcoholic fatty liver disease of rat. Food Chem Toxicol 55:586\u2013591. https:\/\/doi.org\/10.1016\/j.fct.2013.01.022","journal-title":"Food Chem Toxicol"},{"issue":"7","key":"2170_CR140","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1142\/S0192415X18500817","volume":"46","author":"H Jeong","year":"2018","unstructured":"Jeong H, Kim JW, Yang MS, Park C, Kim JH, Lim CW, Kim B (2018) Beneficial effects of Korean red ginseng in the progression of non-alcoholic steatohepatitis via FABP4 modulation. Am J Chin Med 46(7):1581\u20131607. https:\/\/doi.org\/10.1142\/S0192415X18500817","journal-title":"Am J Chin Med"},{"issue":"12","key":"2170_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu11122963","volume":"11","author":"SY Choi","year":"2019","unstructured":"Choi SY, Park JS, Shon CH, Lee CY, Ryu JM, Son DJ, Hwang BY, Yoo HS, Cho YC, Lee J, Kim JW, Roh YS (2019) Fermented Korean red ginseng extract enriched in Rd and Rg3 protects against non-alcoholic fatty liver disease through regulation of mTORC1. Nutrients 11(12):1\u201317. https:\/\/doi.org\/10.3390\/nu11122963","journal-title":"Nutrients"},{"issue":"February","key":"2170_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2021.622841","volume":"12","author":"W Liang","year":"2021","unstructured":"Liang W, Zhou K, Jian P, Chang Z, Zhang Q, Liu Y, Xiao S, Zhang L (2021) Ginsenosides improve nonalcoholic fatty liver disease via integrated regulation of gut microbiota, inflammation and energy homeostasis. Front Pharmacol 12(February):1\u201314. https:\/\/doi.org\/10.3389\/fphar.2021.622841","journal-title":"Front Pharmacol"},{"issue":"2","key":"2170_CR143","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s12072-021-10138-1","volume":"15","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wang N, Tan HY, Li S, Zhang C, Feng Y (2021) Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease. Hep Intl 15(2):350\u2013365. https:\/\/doi.org\/10.1007\/s12072-021-10138-1","journal-title":"Hep Intl"},{"key":"2170_CR144","doi-asserted-by":"publisher","unstructured":"Gu D, Yi H, Jiang K, Fakhar SH, Shi J, He Y, Liu B, Guo Y, Fan X, Li S (2021) Transcriptome analysis reveals the efficacy of ginsenoside-Rg1 in the treatment of nonalcoholic fatty liver disease. Life Sci 267:118986. https:\/\/doi.org\/10.1016\/j.lfs.2020.118986","DOI":"10.1016\/j.lfs.2020.118986"},{"issue":"11","key":"2170_CR145","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1248\/bpb.b18-00132","volume":"41","author":"Y Xu","year":"2018","unstructured":"Xu Y, Yang C, Zhang S, Li J, Xiao Q, Huang W (2018) Ginsenoside Rg1 protects against non-alcoholic fatty liver disease by ameliorating lipid peroxidation, endoplasmic reticulum stress, and inflammasome activation. Biol Pharm Bull 41(11):1638\u20131644. https:\/\/doi.org\/10.1248\/bpb.b18-00132","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"2170_CR146","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/jphp.12487","volume":"68","author":"SB Lee","year":"2016","unstructured":"Lee SB, Cho HI, Jin YW, Lee EK, Ahn JY, Lee SM (2016) Wild ginseng cambial meristematic cells ameliorate hepatic steatosis and mitochondrial dysfunction in high-fat diet-fed mice. J Pharm Pharmacol 68(1):119\u2013127. https:\/\/doi.org\/10.1111\/jphp.12487","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"2170_CR147","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jgr.2020.07.004","volume":"45","author":"JT Hong","year":"2021","unstructured":"Hong JT, Lee MJ, Yoon SJ, Shin SP, Bang CS, Baik GH, Kim DJ, Youn GS, Shin MJ, Ham YL, Suk KT, Kim BS (2021) Effect of Korea red ginseng on nonalcoholic fatty liver disease: an association of gut microbiota with liver function. J Ginseng Res 45(2):316\u2013324. https:\/\/doi.org\/10.1016\/j.jgr.2020.07.004","journal-title":"J Ginseng Res"},{"issue":"3","key":"2170_CR148","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jgr.2015.07.006","volume":"40","author":"M Hong","year":"2016","unstructured":"Hong M, Lee YH, Kim S, Suk KT, Bang CS, Yoon JH, Baik GH, Kim DJ, Kim MJ (2016) Anti-inflammatory and antifatigue effect of Korean red ginseng in patients with nonalcoholic fatty liver diseaseq. J Ginseng Res 40(3):203\u2013210. https:\/\/doi.org\/10.1016\/j.jgr.2015.07.006","journal-title":"J Ginseng Res"},{"key":"2170_CR149","doi-asserted-by":"publisher","unstructured":"Shishtar E, Sievenpiper JL, Djedovic V, Cozma AI, Ha V, Jayalath VH, Jenkins DJA, Meija SB, De Souza RJ, Jovanovski E, Vuksan V (2014) The effect of ginseng (The Genus Panax) on glycemic control: A systematic review and meta-analysis of randomized controlled clinical trials. PLoS One 9(9). https:\/\/doi.org\/10.1371\/journal.pone.0107391","DOI":"10.1371\/journal.pone.0107391"},{"key":"2170_CR150","doi-asserted-by":"publisher","unstructured":"Ziaei R, Ghavami A, Ghaedi E, Hadi A, Javadian P, Clark CCT (2020) The efficacy of ginseng supplementation on plasma lipid concentration in adults: a systematic review and meta-analysis. Complementary Ther Med 48:102239. https:\/\/doi.org\/10.1016\/j.ctim.2019.102239","DOI":"10.1016\/j.ctim.2019.102239"},{"key":"2170_CR151","doi-asserted-by":"publisher","unstructured":"Ghavami A, Ziaei R, Foshati S, Hojati Kermani MA, Zare M, Amani R (2020) Benefits and harms of ginseng supplementation on liver function? A systematic review and meta-analysis. Complementary Therapies in Clinical Prac 39:101173. https:\/\/doi.org\/10.1016\/j.ctcp.2020.101173","DOI":"10.1016\/j.ctcp.2020.101173"},{"key":"2170_CR152","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez-Garc\u00eda D, Granado-Serrano AB, Mart\u00edn-Gari M, Naud\u00ed A, Serrano JC (2019) Efficacy of Panax ginseng supplementation on blood lipid profile. A meta-analysis and systematic review of clinical randomized trials. J Ethnopharmacol 243:112090. https:\/\/doi.org\/10.1016\/j.jep.2019.112090","DOI":"10.1016\/j.jep.2019.112090"},{"issue":"6","key":"2170_CR153","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0091270011407194.Influence","volume":"52","author":"CY Malati","year":"2012","unstructured":"Malati CY, Pharm D, Robertson SM, Pharm D, Hunt JD, Chairez C, Alfaro RM, Kovacs JA, Penzak SR, Pharm D (2012) Influence of Panax ginseng on Cytochrome P450 (CYP)3A and P- glycoprotein (Pgp) Activity in Healthy Subjects. J Clin Pharmacol 52(6):1\u201313. https:\/\/doi.org\/10.1177\/0091270011407194.Influence","journal-title":"J Clin Pharmacol"},{"key":"2170_CR154","doi-asserted-by":"publisher","unstructured":"Yang L, Wang Y, Xu H, Huang G, Zhang Z, Ma Z, Gao Y (2019) Panax ginseng inhibits metabolism of diester alkaloids by downregulating CYP3A4 enzyme activity via the Pregnane X receptor. Evidence-Based Complementary and Alternative Medicine 2019. https:\/\/doi.org\/10.1155\/2019\/3508658","DOI":"10.1155\/2019\/3508658"},{"issue":"6","key":"2170_CR155","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1111\/bcp.13080","volume":"82","author":"MG Kim","year":"2016","unstructured":"Kim MG, Kim Y, Jeon JY, Kim DS (2016) Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach. Br J Clin Pharmacol 82(6):1580\u20131590. https:\/\/doi.org\/10.1111\/bcp.13080","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2170_CR156","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ctim.2006.06.007","volume":"15","author":"N Lynch","year":"2007","unstructured":"Lynch N, Berry D (2007) Differences in perceived risks and benefits of herbal, over-the-counter conventional, and prescribed conventional, medicines, and the implications of this for the safe and effective use of herbal products. Complement Ther Med 15(2):84\u201391. https:\/\/doi.org\/10.1016\/j.ctim.2006.06.007","journal-title":"Complement Ther Med"},{"issue":"3","key":"2170_CR157","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1086\/678173","volume":"105","author":"L Daston","year":"2014","unstructured":"Daston L (2014) The naturalistic fallacy is modern. Isis; an International Review Devoted to the History of Science and Its Cultural Influences 105(3):579\u2013587. https:\/\/doi.org\/10.1086\/678173","journal-title":"Isis; an International Review Devoted to the History of Science and Its Cultural Influences"},{"issue":"1\u20133","key":"2170_CR158","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.toxlet.2004.03.001","volume":"149","author":"R Walker","year":"2004","unstructured":"Walker R (2004) Criteria for risk assessment of botanical food supplements. Toxicol Lett 149(1\u20133):187\u2013195. https:\/\/doi.org\/10.1016\/j.toxlet.2004.03.001","journal-title":"Toxicol Lett"},{"issue":"1","key":"2170_CR159","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/096032719601500102","volume":"15","author":"TYK Chan","year":"1996","unstructured":"Chan TYK, Critchley, julian A. J. H. (1996) Usage and adverse effects of Chinese herbal medicines. Hum Exp Toxicol 15(1):5\u201312. https:\/\/doi.org\/10.1177\/096032719601500102","journal-title":"Hum Exp Toxicol"},{"issue":"1","key":"2170_CR160","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2710.2009.01096.x","volume":"35","author":"G Cravotto","year":"2010","unstructured":"Cravotto G, Boffa L, Genzini L, Garella D (2010) Phytotherapeutics: an evaluation of the potential of 1000 plants. J Clin Pharm Ther 35(1):11\u201348. https:\/\/doi.org\/10.1111\/j.1365-2710.2009.01096.x","journal-title":"J Clin Pharm Ther"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-021-02170-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02170-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T12:13:14Z","timestamp":1644840794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-021-02170-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":160,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2170"],"URL":"https:\/\/doi.org\/10.1007\/s00109-021-02170-3","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"4 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}